This podcast will provide members with an analysis of the Trump administration’s executive order (EO) on drug pricing. We’ll talk through what the EO means for the 340B Drug Pricing Program, the Inflation Reduction Act’s negotiated drug pricing program, and site-neutral payment, and what ASHP will be watching in the coming weeks.
SPEAKERS
Jillanne Schulte Wall, Senior Director, Health & Regulatory Policy ASHP
Tom Kraus, Vice President, Government Relations ASHP
LISTEN ON
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
